Valuation: Dermapharm Holding SE

Market Cap 190.98Cr 213.63Cr 175.85Cr 159.62Cr 298.75Cr 20TCr 304.09Cr 2.1TCr 837.82Cr 11TCr 802.04Cr 784.91Cr 34TCr P/E 2026 *
14.7x
P/E 2027 * 13x
Enterprise Value 272.15Cr 304.43Cr 250.59Cr 227.47Cr 425.74Cr 29TCr 433.34Cr 3TCr 1.19TCr 15TCr 1.14TCr 1.12TCr 48TCr EV / Sales 2026 *
2.25x
EV / Sales 2027 * 2.07x
Free-Float
10.7%
Yield 2026 *
2.65%
Yield 2027 * 2.96%
1 day+0.92%
1 week-0.64%
Current month-1.66%
1 month-2.03%
3 months-7.66%
6 months-15.74%
Current year-2.03%
1 week 37.8
Extreme 37.8
38.95
1 month 37.35
Extreme 37.35
39.7
Current year 34.3
Extreme 34.3
51.9
1 year 32.9
Extreme 32.9
51.9
3 years 30.15
Extreme 30.15
51.9
5 years 30.15
Extreme 30.15
91.95
10 years 21.58
Extreme 21.575
91.95
Manager TitleAgeSince
Chief Executive Officer 64 01/08/2017
Director of Finance/CFO - 01/11/2022
Investor Relations Contact - 01/12/2018
Director TitleAgeSince
Chairman 70 01/08/2017
Director/Board Member 66 01/08/2017
Director/Board Member 78 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
14/05/26 Buy

Chairman

3,80,000 0.7670%
07/01/26 Buy 150 0.0003%
07/01/26 Buy 150 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+0.92%-0.64%+18.62%+4.36% 210.93Cr
+6.63%+8.10%+67.50%+145.20% 1,14800Cr
+1.53%+6.76%+47.22%+89.01% 65TCr
+1.68%+2.10%+27.80%+109.31% 51TCr
+0.73%+2.47%+53.85%+68.96% 38TCr
+3.83%-2.37%+68.14%+42.32% 35TCr
+2.38%+4.27%+33.81%+57.95% 29TCr
+2.26%+3.47%+5.21%+28.92% 26TCr
+1.97%+5.11%+57.74%+76.14% 24TCr
+4.03%+7.84%+40.49%+116.14% 20TCr
Average +1.49%+1.09%+42.04%+73.83% 40.39TCr
Weighted average by Cap. +1.17%+1.50%+49.56%+95.92%

Financials

2026 *2027 *
Net sales 120.86Cr 135.19Cr 111.28Cr 101.01Cr 189.06Cr 13TCr 192.43Cr 1.33TCr 530.19Cr 6.76TCr 507.55Cr 496.71Cr 21TCr 125.45Cr 140.32Cr 115.51Cr 104.85Cr 196.24Cr 13TCr 199.74Cr 1.38TCr 550.33Cr 7.02TCr 526.82Cr 515.57Cr 22TCr
Net income 14Cr 15Cr 13Cr 11Cr 21Cr 1.46TCr 22Cr 151.08Cr 60Cr 767.53Cr 58Cr 56Cr 2.42TCr 16Cr 17Cr 14Cr 13Cr 24Cr 1.65TCr 25Cr 170.97Cr 68Cr 868.62Cr 65Cr 64Cr 2.74TCr
Net Debt 81Cr 91Cr 75Cr 68Cr 126.98Cr 8.64TCr 129.25Cr 893.49Cr 356.11Cr 4.54TCr 340.9Cr 333.62Cr 14TCr 69Cr 77Cr 63Cr 57Cr 107.45Cr 7.31TCr 109.37Cr 756.05Cr 301.33Cr 3.84TCr 288.46Cr 282.3Cr 12TCr
Projected Income Statement - Annual - Dermapharm Holding SE
Logo Dermapharm Holding SE
Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Employees
3,619
Date Price Change Volume
29/26/29 €38.55 +0.92% 17,671
28/26/28 €38.20 -0.52% 15,757
27/26/27 €38.40 +1.45% 11,217
26/26/26 €37.85 -1.43% 10,131
23/26/23 €38.40 -0.78% 18,324
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Dermapharm Holding SE
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
38.55EUR
Average target price
51.00EUR
Spread / Average Target
+32.30%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Dermapharm Holding SE